It took seven years and a $245 million merger, but the DuraSeal Spine Sealant finally hit the market in the U.S.
Neurological
Welcome to MassDevice's Neurological Hub, your resource for the latest news in the neurological device space. Stay informed about the innovations and business news shaping the neurological industry.
🧠 Narrow your focus with these categories:
Neuromodulation/Neurostimulation | Bioelectronic Medicine | Pain Management | Brain-Computer Interfaces
Here are the top neurological device features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ Analysts see $400B BCI opportunity
+ The top 10 neurotech stories of the year so far
+ 7 neurotech companies you need to know
+ Brain breakthroughs: Aprinoia Therapeutics’ harnesses AI and strategic partnerships to propel neurodegenerative disease research
+ 7 brain-computer interface companies you need to know
+ Natalizumab and PML: The complex dance of benefit and risk for MS
Latest Neurological News
UPDATE: Covidien completes Aspect Medical Systems acquisition
Covidien completed its $210 million acquisition of Aspect Medical Systems Inc.
Q3 sales fall, net losses expand for NeuroMetrix
Sales slumped and net losses grew during the third quarter for NeuroMetrix Inc., as hospitals kept less of its nerve testing consumables on hand.
The Waltham, Mass.-based company posted sales of $6.3 million during the three months ended Sept. 30, down 10.6 percent compared with $7.1 million during the same period last year. Net losses widened 18 percent to $9.3 million, compared with $7.9 million during the third quarter of 2008.
Invivo Therapeutics resumes second primate study
InVivo Therapeutics Inc. is back on track with a second primate study, just a month after filing a lawsuit against its former contract research facility.
CEO Frank Reynolds told MassDevice in an email that the Cambridge, Mass.-based spinal tissue regeneration developer’s second primate study is already eight weeks in, having begun on August 20. Reynolds said the company went back to St. Kitts Biomedical Research Facility in St. Kitts, U.S. Virgin Islands, the site of its initial primate study back in 2007.
Lawsuits pile up opposing Covidien’s Aspect Medical buyout
Two separate shareholder groups have filed suit to overturn a proposed $210 million buyout of Aspect Medical Systems Inc. by Covidien plc.
Aspect Medical Systems shareholders sue to block Covidien buyout
Shareholders of Aspect Medical Systems Inc. filed a lawsuit to block a proposed $210 million acquisition by Covidien.
The deal would see the Mansfield, Mass.-based medical devices giant pay $12 per share for Aspect, a Norwood, Mass.-based maker of brain monitoring equipment that measures the effects of anesthesia and sedation.
InVivo Therapeutics sues Oregon Health & Science University over primate study
A lawsuit filed earlier this month by Invivo Therapeutics Inc.in the U.S. District Court for Massachusetts is shedding new light on the status of Cambridge, Mass.-based company’s quest to cure paralysis.
Deerfield Management cashes in on NxStage
A New York hedge fund specializing in medical-device and biotech plays has sold off 4.4 percent of its overall stake in NxStage Medical Inc.
Former Caliper CFO jumps to NeuroMetrix
NeuroMetrix Inc. tapped the former CFO at Caliper Life Sciences to be its finances chief, effective immediately.
The Waltham, Mass.-based nerve test equipment maker said Higgins, a 30-year life sciences veteran, started at Caliper in 2005. Prior to that, he began a stint in 1998 as operations vice president and CFO at test & measurement systems provider V.I. Technologies Inc., running its plasma manufacturing business until the company sold it in 2001. He also spent 13 years at Cabot Corp., rising to president of its Distrigas of Mass. subsidiary.
NeuroMetrix to raise nearly $19 million in stock sale
NeuroMetrix Inc. won commitments from institutional investors to buy about $18.7 million worth of its stock — 8,816,521 shares and warrants to purchase up to 8,375,695 additional shares — in a private placement for $2.12 per share.
The Waltham, Mass.-based nerve test equipment manufacturer said the offering is expected to close “later this week.”
It plans to use the cash to bolster its direct sales force in the U.S., boost its profile overseas, pay for clinical trials and get its lead potassium channel blocker compound to a Phase I milestone.
Study of cerebral aneurysm coiling has good news for Boston Scientific, J&J’s Cordis
A study evaluating the risks of re-treating brain aneurysms after endovascular coil embolization bore some good news for Boston Scientific and Johnson & Johnson’s Cordis Corp. subsidiary.
The study‘s authors — two of whom received grants or honoraria from the two device makers — examined the results in 311 cases in which patients were treated again after having coils implanted in their brains via catheter. The study indicated that the risk of death or permanent major disability was 1.28 percent, or just more than one in 100.
The study was published in Neurosurgery magazine.
